PT1333848E - Compostos derivados de phyllantus para a prevencao e/ou o tratamento de doencas associadas com um retrovirus - Google Patents
Compostos derivados de phyllantus para a prevencao e/ou o tratamento de doencas associadas com um retrovirusInfo
- Publication number
- PT1333848E PT1333848E PT01986262T PT01986262T PT1333848E PT 1333848 E PT1333848 E PT 1333848E PT 01986262 T PT01986262 T PT 01986262T PT 01986262 T PT01986262 T PT 01986262T PT 1333848 E PT1333848 E PT 1333848E
- Authority
- PT
- Portugal
- Prior art keywords
- retrovirus
- prevention
- treatment
- diseases associated
- phyllantus
- Prior art date
Links
- 241001430294 unidentified retrovirus Species 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 229920002824 gallotannin Polymers 0.000 abstract 4
- TUSDEZXZIZRFGC-XIGLUPEJSA-N corilagin Chemical compound O([C@H]1[C@H](O)[C@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@@H](O1)[C@H]2O)C(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-XIGLUPEJSA-N 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 abstract 2
- 241001130943 Phyllanthus <Aves> Species 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 abstract 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 abstract 1
- 229920002786 Corilagin Polymers 0.000 abstract 1
- JQQBXPCJFAKSPG-SVYIMCMUSA-N Geraniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]3OC(=O)C=4C=C(O)C(O)=C5O[C@@]6(O)C(=O)C=C([C@@H](C5=4)C6(O)O)C(=O)O[C@H]4[C@@H]3OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@H]4O2)=C1 JQQBXPCJFAKSPG-SVYIMCMUSA-N 0.000 abstract 1
- 229920000061 Geraniin Polymers 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 244000173207 Phyllanthus amarus Species 0.000 abstract 1
- CPWYQGWOJMNXGJ-UHFFFAOYSA-N corilagin Natural products OC1C2COC(=O)c3c(O)c(O)c(O)c(O)c3c4c(O)c(O)c(O)c(O)c4C(=O)OC1C(O)C(OC(=O)c5cc(O)c(O)c(O)c5)O2 CPWYQGWOJMNXGJ-UHFFFAOYSA-N 0.000 abstract 1
- 229920001968 ellagitannin Polymers 0.000 abstract 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 abstract 1
- GJMUCSXZXBCQRZ-UHFFFAOYSA-N geraniin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4cc(O)c(O)c(O)c4c5cc(C(=O)C67OC3C(O6)C2OC(=O)c8cc(O)c(O)c9OC%10(O)C(C(=CC(=O)C%10(O)O)C7=O)c89)c(O)c(O)c5O GJMUCSXZXBCQRZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00121852 | 2000-10-06 | ||
| EP01114008 | 2001-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1333848E true PT1333848E (pt) | 2006-08-31 |
Family
ID=26071484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01986262T PT1333848E (pt) | 2000-10-06 | 2001-10-05 | Compostos derivados de phyllantus para a prevencao e/ou o tratamento de doencas associadas com um retrovirus |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040161477A1 (pt) |
| EP (1) | EP1333848B1 (pt) |
| JP (1) | JP2004513092A (pt) |
| AT (1) | ATE322278T1 (pt) |
| AU (1) | AU2002220594A1 (pt) |
| CA (1) | CA2424869A1 (pt) |
| DE (1) | DE60118592T2 (pt) |
| ES (1) | ES2261507T3 (pt) |
| PT (1) | PT1333848E (pt) |
| WO (1) | WO2002028403A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1326624B1 (de) | 2000-10-06 | 2004-09-08 | Phytrix AG | Verfahren zur herstellung von phyllanthusextrakten |
| EP2116253A1 (en) | 2008-05-07 | 2009-11-11 | Phytrix JV, LLC | Novel phyllanthus extract |
| WO2011085454A1 (en) * | 2010-01-18 | 2011-07-21 | Katholieke Universiteit Leuven K.U.Leuven R&D | Gp120 -binding benzene compounds and saccharide compounds |
| KR101604347B1 (ko) * | 2013-07-01 | 2016-03-17 | 한국생명공학연구원 | 피스타시아 웨인마니폴리아 추출물 또는 이의 분획물을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 |
| CN103480178B (zh) * | 2013-09-30 | 2016-09-28 | 新疆大学 | 一种亚临界水提取雪菊中活性成分的方法 |
| CN103976356B (zh) * | 2014-05-07 | 2015-08-26 | 王浩 | 一种减肥食品及其制备方法 |
| CN110665002B (zh) * | 2019-10-29 | 2023-01-24 | 信阳市动物疫病预防控制中心 | 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法 |
| CN111658631A (zh) * | 2020-06-11 | 2020-09-15 | 广东盛普生命科技有限公司 | 没食子酸及其衍生物和结构类似物在制备抗冠状病毒药物方面的应用 |
| CN112022867B (zh) * | 2020-06-18 | 2022-05-13 | 浙江省疾病预防控制中心 | 老鹳草素在制备抗新型冠状病毒药中的应用 |
| EP3954379A1 (en) * | 2020-08-12 | 2022-02-16 | HFM - Hybrid Fusion Medicals, GmbH | Compositions comprising phyllanthus extract for use in the treatment or prevention of a sars-cov-2 infection and/or at least one symptom of covid-19 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US28754A (en) * | 1860-06-19 | Congress boot | ||
| US33275A (en) * | 1861-09-10 | Improved pipe-joi-nt | ||
| US4388457A (en) * | 1982-02-11 | 1983-06-14 | University Patents, Inc. | Phyllanthostatin compounds |
| US4673575A (en) * | 1985-04-26 | 1987-06-16 | Fox Chase Cancer Center | Composition, pharmaceutical preparation and method for treating viral hepatitus |
| US4937074A (en) * | 1988-03-29 | 1990-06-26 | Fox Chase Cancer Center | Method of treating retrovirus infection |
| CA2001898A1 (en) * | 1988-10-31 | 1990-04-30 | Kuo-Hsiung Lee | Inhibition of human retroviruses |
| US5854233A (en) * | 1993-09-08 | 1998-12-29 | Pharmacy And Therapeutic Advisory Consultancy Ltd. | Method of treating liver disease and like indications with vasodilating agents |
| US5529778A (en) * | 1994-09-13 | 1996-06-25 | Rohatgi; Surendra | Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same |
| US5571441A (en) * | 1994-11-01 | 1996-11-05 | The Procter & Gamble Company | Nutrient supplement compositions providing physiologic feedback |
| US5648089A (en) * | 1995-07-03 | 1997-07-15 | Shawkat; Tarek | Extract solution and herbal mixture for treatment of hepatitis |
| US6136316A (en) * | 1996-04-17 | 2000-10-24 | Dabur Research Foundation | Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection |
| DE19919585A1 (de) * | 1999-04-29 | 2000-12-07 | Cmi Ag | Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen |
-
2001
- 2001-10-05 US US10/398,379 patent/US20040161477A1/en not_active Abandoned
- 2001-10-05 PT PT01986262T patent/PT1333848E/pt unknown
- 2001-10-05 EP EP01986262A patent/EP1333848B1/en not_active Expired - Lifetime
- 2001-10-05 ES ES01986262T patent/ES2261507T3/es not_active Expired - Lifetime
- 2001-10-05 AT AT01986262T patent/ATE322278T1/de not_active IP Right Cessation
- 2001-10-05 WO PCT/EP2001/011524 patent/WO2002028403A1/en active IP Right Grant
- 2001-10-05 JP JP2002532227A patent/JP2004513092A/ja active Pending
- 2001-10-05 DE DE60118592T patent/DE60118592T2/de not_active Expired - Lifetime
- 2001-10-05 AU AU2002220594A patent/AU2002220594A1/en not_active Abandoned
- 2001-10-05 CA CA002424869A patent/CA2424869A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1333848B1 (en) | 2006-04-05 |
| DE60118592T2 (de) | 2007-05-16 |
| DE60118592D1 (de) | 2006-05-18 |
| CA2424869A1 (en) | 2002-04-11 |
| EP1333848A1 (en) | 2003-08-13 |
| US20040161477A1 (en) | 2004-08-19 |
| ES2261507T3 (es) | 2006-11-16 |
| WO2002028403A1 (en) | 2002-04-11 |
| AU2002220594A1 (en) | 2002-04-15 |
| JP2004513092A (ja) | 2004-04-30 |
| ATE322278T1 (de) | 2006-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1333848E (pt) | Compostos derivados de phyllantus para a prevencao e/ou o tratamento de doencas associadas com um retrovirus | |
| ATE264914T1 (de) | Antivirale proteine, dafür kodierende dna, und deren verwendung | |
| BR0214407A (pt) | Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina | |
| BR9710355A (pt) | Composição útil para o tratamento de infecções virais em um mamìfero, processo para tratar uma infecção viral em um mamìfero, e, produto medicinal. | |
| TR200003113T2 (tr) | 3-(amino- veya aminoalkil) piridinon türevleri ve bunların HIV bağımlı hastalıkların tedavisinde kullanılması. | |
| BRPI0518861B8 (pt) | compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e uso de quantidade terapeutica ou profilaticamente eficaz de composto ou de composição farmacêutica | |
| ES2142781T3 (es) | Pomada vegetal. | |
| BR9909730A (pt) | Dihidropirimidinas | |
| BR9406509A (pt) | Compostos processo sua preparação uso dos mesmos composições farmaceuticas e processo para profilaxia e para tratamento terapeutico de malária e doenças causadas por leishmania toxoplasma gondil pneumocy | |
| BR9811298A (pt) | Uso de um composto de vanádio fisiologicamente aceitável | |
| KR970704768A (ko) | 사람 면역결핍증 바이러스의 증식을 억제하는 화합물 및 방법(Compounds and Methods for Inhibiting Propagation of Human Immunoefficiency Virus) | |
| AP2000001971A0 (en) | Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine. | |
| WO2005097618A3 (en) | Low dose therapy for treating viral infections | |
| DE69403063D1 (de) | Gegen viren wirksame naphtochinon-verbindungen, zusammensetzungen und deren verwendungen | |
| ES2086274T3 (es) | Preparaciones de especies de crataegus, composiciones farmaceuticas y su uso para prevenir la muerte subita debida a ataque cardiaco y las lesiones cardiovasculares provocadas por reperfusion. | |
| WO2005097179A3 (fr) | Antigene tat stabilise et ses applications pour la vaccination anti-vih. | |
| WO1998018477A3 (en) | Pharmaceutical compositions containing lamivudine and zidovudine | |
| ES2134259T3 (es) | Compuestos antiviricos calanolidas, composiciones y utilizacion de los mismos. | |
| BR9509925A (pt) | Composição e uso da composição para prevenção ou tratamento de infecção por hiv-1 | |
| BR0306778A (pt) | Derivados de carboxamidina e seu uso no tratamento de doenças vasculares | |
| NO20003866L (no) | Urte-antiviralt middel | |
| HN2001000204A (es) | Amidas de acido fenilciclohexanocarboxilico sustituido y su uso | |
| Tejaswi et al. | Herbal medicine for Leishmaniasis: A Review | |
| BR0207931A (pt) | Anticorpos naturais ativos contra vìrus hiv | |
| AU2880495A (en) | Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses |